Bruker AI Stock Analysis
Want to see BRKR full AI Analyst Report?
Bruker (BRKR) AI Stock Analysis
Bruker
(NASDAQ:BRKR)
The score is held back mainly by weakened profitability (GAAP losses and sharply compressed operating margins) despite strong revenue growth and improved free cash flow. Technicals are supportive with the stock in an uptrend and momentum indicators constructive. Guidance and commentary add confidence around non-GAAP margin and EPS improvement, but valuation remains challenged due to the negative P/E and only a modest dividend yield.
Bruker Key Performance Indicators (KPIs)
Revenue by GeographyShows where Bruker earns sales across regions, highlighting which markets drive growth and how diversified the company is. Reveals exposure to regional economic slowdowns, currency swings, and localized demand for scientific instruments and services.
The geographic mix is shifting: North America and Europe (ex‑Germany) are now the steady engines behind revenue and non‑GAAP margin improvement, while China/APAC remain choppy—China plunged from prior highs into early‑2026 then partially rebounded, keeping regional growth uneven. Management’s commentary lines up: strong deep‑tech and semiconductor bookings outside China underpin medium‑term upside, but long lead times, FX/tariff effects and a disclosed ~$20M Q3→Q4 timing shift mean organic growth will be lumpy quarter to quarter despite improving margins.
Bruker (BRKR) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $9.41B
- Dividend Yield
- 0.32%
- Average Volume (3M)
- 2.31M
- Price to Earnings (P/E)
- -56.0
- Beta (1Y)
- 1.17
- Revenue Growth
- 2.16%
- EPS Growth
- -604.24%
- Country
- US
- Employees
- 11,085
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
Bruker Business Overview & Revenue Model
Company Description
Bruker Corporation stands as a prominent global developer, manufacturer, and distributor of cutting-edge scientific instruments, alongside comprehensive analytical and diagnostic solutions. Its operations are structured across three distinct segments...
How the Company Makes Money
Bruker makes money primarily by selling scientific and diagnostic instruments and then generating recurring revenue from the installed base through services, software, and consumables. Key revenue streams typically include: (1) Instrument and system...
Bruker Earnings Call Summary
The call was predominantly positive. Bruker reported significant margin expansion, 24.4% non-GAAP EPS growth, improved free cash flow, debt reduction, sustained bookings above one, strong China and semiconductor metrology bookings, and reaffirmed full-year guidance. These positives were partly offset by modest organic revenue growth, BSI revenue pressure from semiconductor pushouts, weakness in selected academic and government and industrial markets, a $175 million Spatial Biology goodwill impairment, and a GAAP loss. Management expressed increased confidence in the fourth quarter and meaningful growth and margin improvement in 2027.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
For fiscal year 2026, Bruker expects reported revenue of $3.52 billion-$3.56 billion, representing reported growth of 2.5%-3.5%, organic revenue growth of 1%-2%, contribution from acquisition to approximately 1.5%, currency to be approximately neutral, non-GAAP operating margin expansion of 250-300 basis points, and non-GAAP EPS of $2.10-$2.15, up 15%-17%; for the fourth quarter, it expects organic revenue to grow in the lower mid-single digits percentage year over year, with meaningful sequential and year-over-year increases in operating margin and EPS, a likely $1 billion in revenue quarter, and operating margin stepping up to the high teens, while for fiscal year 2027 it is committed to double-digit EPS growth, is seeking greater than 100 basis points of further operating margin expansion, and expects organic growth at least to the lower mid-single digits; BMID is expected to be a high single-digit growth area long term, and Bruker targets reducing its tax rate by at least 50 basis points on a year-over-year basis in 2027.
Bruker Financial Statement Overview
Summary
Mixed fundamentals. Revenue is strong (TTM up 38.6%) and free cash flow rebounded meaningfully (TTM FCF ~$245M), and leverage has improved (debt-to-equity ~0.80x TTM). However, profitability has deteriorated sharply with a GAAP loss in TTM (net margin -2.0%) and very thin operating profitability (~0.5% EBIT margin TTM), making earnings normalization the key financial risk.
Income Statement
44NeutralBalance Sheet
58NeutralCash Flow
63Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.51B | 3.44B | 3.37B | 2.96B | 2.53B | 2.42B |
| Gross Profit | 1.68B | 1.58B | 1.65B | 1.51B | 1.31B | 1.21B |
| EBITDA | 123.20M | 302.60M | 438.60M | 675.50M | 518.70M | 497.00M |
| Net Income | -123.40M | -8.60M | 113.10M | 427.20M | 296.60M | 277.10M |
Balance Sheet | ||||||
| Total Assets | 5.83B | 6.24B | 5.81B | 4.25B | 3.61B | 3.65B |
| Cash, Cash Equivalents and Short-Term Investments | 167.00M | 298.80M | 183.40M | 488.30M | 645.50M | 1.17B |
| Total Debt | 1.71B | 2.04B | 2.25B | 1.38B | 1.27B | 1.39B |
| Total Liabilities | 3.49B | 3.73B | 3.99B | 2.84B | 2.48B | 2.57B |
| Stockholders Equity | 2.29B | 2.46B | 1.78B | 1.38B | 1.11B | 1.07B |
Cash Flow | ||||||
| Free Cash Flow | 244.70M | 13.90M | 136.00M | 243.20M | 145.20M | 190.40M |
| Operating Cash Flow | 341.80M | 134.10M | 251.30M | 350.10M | 274.40M | 282.40M |
| Investing Cash Flow | -193.20M | -196.50M | -1.76B | -326.00M | -251.60M | -192.40M |
| Financing Cash Flow | -333.40M | 135.10M | 1.23B | -193.40M | -415.30M | 318.70M |
Bruker Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BRKR, the sentiment is Positive. The current price of 61.59 is above the 20-day moving average (MA) of 59.69, above the 50-day MA of 59.47, and above the 200-day MA of 50.75, indicating a bullish trend. The MACD of 0.84 indicates Negative momentum. The RSI at 52.53 is Neutral, neither overbought nor oversold. The STOCH value of 44.63 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BRKR.
Bruker Risk Analysis
Bruker disclosed 42 risk factors in its most recent earnings report. Bruker reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksBruker Peers Comparison
Overall Rating
GEHC79Outperform
BIO78Outperform
BRKR61Neutral
CTKB53Neutral
PACB44Neutral
QTRX36Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 79Outperform | $37.54B | 17.51 | 19.85% | 0.17% | 6.87% | -2.26% | |
| 78Outperform | $9.86B | 9.60 | 14.07% | ― | 1.38% | ― | |
| 61Neutral | $9.41B | -56.04 | -5.15% | 0.32% | 2.16% | -604.24% | |
| 53Neutral | $763.78M | -9.27 | -24.74% | ― | 5.50% | -524.33% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 44Neutral | $613.34M | -4.67 | 604.22% | ― | 4.41% | 74.75% | |
| 36Underperform | $139.11M | -1.24 | -42.99% | ― | 13.78% | -1.29% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| BRKR | Bruker Corporation | 61.59 | 20.00 | 48.08% | |
| BIO | Bio-Rad Laboratories | 366.36 | 62.30 | 20.49% | |
| PACB | Pacific Biosciences | 1.96 | 0.39 | 24.84% | |
| QTRX | Quanterix | 2.93 | -2.60 | -47.02% | |
| CTKB | Cytek Biosciences, Inc. | 5.84 | 0.55 | 10.40% | |
| GEHC | Ge Healthcare Technologies Inc. | 83.02 | 12.53 | 17.78% |
Bruker Corporate Events
Bruker Completes Reorganization and Updates Segment Reporting
NeutralEffective July 1, 2026, Bruker completed a reorganization intended to streamline its structure and support decision-making, accountability, customer focus and innovation. The company replaced its previous four-segment reporting structure with BSI BIO...
Bruker Declares Quarterly Dividend on Preferred Shares
PositiveOn October 29, 2026, Bruker Corporation’s Board of Directors declared a quarterly cash dividend of $3.9844 per share on its 6.375% Mandatory Convertible Preferred Stock, Series A, with a par value of $0.01 per share. The dividend is payable on Decemb...
Bruker Board Declares Quarterly Cash Dividend for Shareholders
PositiveOn August 14, 2026, Bruker Corporation’s Board of Directors declared a quarterly cash dividend of $0.05 per share on its common stock, with a par value of $0.01 per share. The dividend is scheduled to be paid on October 7, 2026, to shareholders of re...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 05, 2026
